Related Experiment Video
Updated: Mar 22, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.6K
Workforce unavailability in Parkinson's disease
J Timpka1,2, J Svensson3, M H Nilsson4,5
1Department of Clinical Sciences Lund, Neurology, Faculty of Medicine, Lund University, Lund, Sweden.
Acta Neurologica Scandinavica
|April 14, 2016
Summary
Parkinson's disease (PD) is linked to earlier workforce unavailability. Anxiety and age are significant factors contributing to this, with anxiety being a potentially modifiable target for intervention.
Area of Science:
- Neurology
- Occupational Health
- Social Sciences
Background:
- Parkinson's disease (PD) leads to premature workforce unavailability, impacting individuals and social insurance systems.
- Workforce participation is crucial for social interaction and personal identity beyond economic benefits.
- Understanding factors contributing to workforce unavailability in PD is essential for targeted support.
Purpose of the Study:
- To identify key factors associated with workforce unavailability in individuals with Parkinson's disease (PD).
- To explore the relationship between demographic and clinical variables and employment status in PD patients.
Main Methods:
- Cross-sectional registry study utilizing data from the Swedish national quality registry for PD.
- Inclusion criteria: individuals with PD in Skåne County, Sweden, younger than 65 years.
- Statistical analysis involved simple and multiple logistic regression to identify significant factors.
Main Results:
- 99 individuals with PD were included (59 available, 40 unavailable in the workforce).
- Increased age (OR per year: 1.47) was significantly associated with workforce unavailability.
- Anxiety (OR: 6.81) was also a significant contributing factor to workforce unavailability.
Conclusions:
- Age and anxiety are identified as potential contributors to workforce unavailability in Parkinson's disease (PD).
- Anxiety, a potentially modifiable factor, warrants further investigation.
- Prospective studies are needed to confirm these findings and clarify the causal relationship between anxiety and workforce unavailability.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:37Neural Regulation
44.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.6K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
333
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
333